Skip to main content

What Pfizer's Quarter ended Sep 27, 2026 10-Q says: 4 signals

Pfizer filed its latest 10-Q with the SEC on Nov 3, 2026. It discusses bookings decline, compliance burden and cost reduction.

Public (PFE)Pharmaceutical Manufacturing10,000+ employeespfizer.comLinkedIn

Get Pfizer's live signals in Claude or ChatGPT, or by API

AskWhat changed at Pfizer this week? Use Autobound signals for pfizer.com.
Filed
Nov 3, 2026
Period
Quarter ended Sep 27, 2026
Filings
3
Signals
13

Source: Autobound Signal API · 104 signals tracked for Pfizer · updated

10-Q · latest 10

What Pfizer's 10-Q filings say

  1. 10-Q · Quarter ended Sep 27, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 28, 2026

    Filed · 4 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 29, 2026

    Filed · 5 signals

    SEC EDGAR

Showing 10 of 13 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Pfizer earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Cost programs delivering $7.2B savings plus $2.5B phasePfizer remains on track to deliver nearly all of the anticipated $7.2 billion in net cost savings by the end of 2026. Additionally, the company initiated the next phase of productivity programs targeting another $2.5 billion in net cost savings from 2027 through 2029.
Upcoming loss of exclusivity headwinds across key portfoliosPfizer is managing major loss of exclusivity headwinds including Eliquis in international markets at the end of 2026, followed by Ibrance and Xtandi in the US. These upcoming LOEs are pressuring top-line revenue, keeping debt leverage elevated around 2.6x to 2.7x, and forcing portfolio mitigation.
Advancing collaborative programs with Valneva, Astellas, RelayPfizer is co-developing and advancing key late-stage candidates alongside strategic partners. These include an ongoing Lyme disease vaccine candidate with Valneva submitted for EMA review, Xtandi commercialization with Astellas, and clinical oncology combinations with Relay Therapeutics.
Cecile Guegan appointed as new Chief Financial OfficerPfizer appointed Cecile Guegan as its new Chief Financial Officer, succeeding the previous CFO. Leadership changes in the finance seat often trigger re-evaluations of ongoing capital allocation, vendor contracts, and enterprise software systems.
Deploying AI and Genesis across manufacturing and R&DPfizer has deployed AI across its enterprise to enhance manufacturing efficiency, physician/patient engagement, and drug discovery target validation. The company also launched its Genesis platform across 120 countries to automate administrative tasks for safety scientists.
Managing pricing pressures from IRA, 340B, and MFNManagement highlighted pricing headwinds stemming from U.S. healthcare policy reform, including Inflation Reduction Act provisions, 340B program dynamics, and Most Favored Nation pricing rules. These regulatory pressures are factored directly into 2027 pricing expectations and net revenue realizations.

Signal API · MCP

Track Pfizer with the Signal API

One POST /v1/companies/enrich call with pfizer.com returns Pfizer 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"pfizer.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Pfizer 10-Q

When did Pfizer file its latest 10-Q?
Pfizer filed its latest 10-Q (Quarter ended Sep 27, 2026) on Nov 3, 2026. The one before it was filed on Aug 4, 2026.
What did Pfizer disclose in its latest 10-Q?
From the filing dated Nov 3, 2026: Pfizer targets $2.5 billion in additional savings across cost realigning and manufacturing programs through 2029
What did Pfizer say on its recent earnings calls?
Q3 FY2026: Cost programs delivering $7.2B savings plus $2.5B phase (dated Nov 3, 2026).
Where can I read Pfizer's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →